Toward the development of defined microbial therapeutics.

Area of Science:

• Microbiology
• Gastroenterology
• Immunology

Background:

• The gut microbiota, a complex ecosystem of microorganisms in the mammalian gastrointestinal tract, profoundly influences host health.
• Microbiota-based therapies, such as fecal microbiota transplantation, show promise for treating conditions like C. difficile infections, IBD, GVHD, and cancer.

Purpose of the Study:

• To highlight the therapeutic potential of the gut microbiota.
• To address challenges in current microbiota-based therapies, including understanding active components and risks.
• To emphasize the need for identifying specific effector microbes and developing defined microbial therapeutics.

Main Methods:

• Review of clinical studies on fecal microbiota transplantation.
• Discussion of ongoing research efforts to identify causative microbial agents.
• Exploration of strategies for developing defined microbial therapeutics.

Main Results:

• Fecal microbiota transplantation demonstrates efficacy in various diseases.
• Lack of understanding of specific microbial components and associated risks hinders clinical application.
• Identification of effector microbes is crucial for establishing causality.

Conclusions:

• Microbiota-targeted therapies hold significant therapeutic potential.
• Developing well-characterized microbial therapeutics based on defined components is essential for clinical advancement.
• Further research into effector microbes will enhance the precision and safety of microbiota-based treatments.